Global Consortium Launches Collaboration To Accelerate Development Of Novel TB Drug Regimens
GSK: First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis
“[On Thursday,] a consortium of philanthropic, non-profit, and private sector organizations launched a collaboration that aims to accelerate the development of novel ‘pan-TB’ drug regimens for the treatment of tuberculosis (TB) that are ready for phase 3 development. The regimens will be designed to have little to no drug resistance and an acceptable safety profile, and be better-tolerated, shorter in duration, and simpler to use than existing options. Such regimens are intended to be a central component of efforts to address the current complexities and challenges of TB treatment…” (2/27).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.